Skip to content
DataLookout
Menu

NCT07938840

Opioid-Free Total Shoulder With Suzetrigine

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pain Numeric Rating Scale (NRS)
Timeframe: 24 hours post-surgery

Secondary (8)

Pain Numeric Rating Scale (NRS)
Morphine Milligram Equivalents (MME)
Rescue opioid analgesia
Patient satisfaction with overall pain control
Hospital length of stay
Show 3 moreShow less
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Single Assessment Numeric Evaluation (SANE)
Simple Shoulder Test (SST)

Arms and interventions

Standard Opioid-Containing PathwayActive comparator

Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

Opioid-Free Suzetrigine PathwayExperimental

Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

Drugs: Suzetrigine

Procedures: Shoulder Arthroplasty

Sites

1 site in 1 country

  • OrthoCarolina Research InstituteCharlotte, North Carolina, United States